SCHEMBL3265804

SCHEMBL3265804

c1ccc(NCCNc2ccccn2)nc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.70
CYP2C19 P33261 1/20 0.68
CXCR4 P61073 1/20 0.65
FABP1 P07148 1/20 0.63
FABP6 P51161 1/20 0.63
ALDH1A1 P00352 2/20 0.55
KDM4E B2RXH2 1/20 0.55
HPGD P15428 1/20 0.55
MEN1 O00255 1/20 0.54
MAPK10 P53779 1/20 0.54
GFER P55789 1/20 0.54
KMT2A Q03164 1/20 0.54
CYP2D6 P10635 1/20 0.53
GAA P10253 2/20 0.52
FDPS P14324 1/20 0.52
NPC1 O15118 3/20 0.50
RAB9A P51151 3/20 0.50
PKM P14618 1/20 0.50
TP53 P04637 1/20 0.50
TSHR P16473 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1837886 0.95 CYP1A2 (0.66) CYP1A2CYP2C19CXCR4FABP1FABP6
SCHEMBL19322388 0.91 ALDH1A1 (0.67) CYP1A2CYP2C19CXCR4FABP1FABP6
SCHEMBL10861718 0.91 CYP1A2 (0.66) CYP1A2CYP2C19CXCR4FABP1FABP6
SCHEMBL1344396 0.89 CYP2C19 (0.62) CYP1A2CYP2C19CXCR4FABP1FABP6
SCHEMBL9644591 0.89 CYP1A2 (0.63) CYP1A2CYP2C19CXCR4FABP1FABP6
SCHEMBL10858528 0.89 CYP1A2 (0.63) CYP1A2CYP2C19CXCR4FABP1FABP6
SCHEMBL1831590 0.88 CYP1A2 (0.58) CYP1A2CYP2C19CXCR4FABP1FABP6
SCHEMBL21872244 0.88 CXCR4 (0.58) CYP1A2CYP2C19CXCR4FABP1FABP6
Hydrochloric Acid SCHEMBL8177967 0.88 CYP2C19 (0.61) CYP1A2CYP2C19CXCR4FABP1FABP6
SCHEMBL8536507 0.87 CYP1A2 (0.61) CYP1A2CYP2C19CXCR4FABP1FABP6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0433642-B1 Karl-Fischer reagent and process for the determination of water by using the reagent MERCK PATENT GMBH (DE) 1997-02-26 EP claimed
US-5086000-A PROCESS FOR THE PREPARATION OF ALKYLENE-BIS(2-PYRIDYLAMINE) COMPOUNDS AND KARL FISCHER REAGENTS AND METHODS UTILIZING SUCH COMPOUNDS MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1992-02-04 US claimed
JP-3170460-A None JP disclosed
US-9074128-B2 Metal complexes having azaborol ligands and electronic device having the same MERCK PATENT GMBH (DE) 2015-07-07 US disclosed
US-8722898-B2 2014-05-13 US disclosed
US-20120004407-A1 METAL COMPLEXES HAVING AZABOROL LIGANDS AND ELECTRONIC DEVICE HAVING THE SAME MERCK PATENT GMBH (DE) 2012-01-05 US disclosed
WO-2010099852-A1 METAL COMPLEXES HAVING AZABOROL LIGANDS AND ELECTRONIC DEVICE HAVING THE SAME MERCK PATENT GMBH (DE) 2010-09-10 WO disclosed
EP-0433642-B1 Karl-Fischer reagent and process for the determination of water by using the reagent MERCK PATENT GMBH (DE) 1997-02-26 EP disclosed
US-5086000-A PROCESS FOR THE PREPARATION OF ALKYLENE-BIS(2-PYRIDYLAMINE) COMPOUNDS AND KARL FISCHER REAGENTS AND METHODS UTILIZING SUCH COMPOUNDS MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1992-02-04 US disclosed
JP-H03170460-A PROCESS FOR PREPARATION OF ALKYLENE-BIS(2-PYRIDYLAMINE) COMPOUND MERCK PATENT GMBH 1991-07-24 JP disclosed
EP-0433642-A1 Karl-Fischer reagent and process for the determination of water by using the reagent MERCK PATENT GmbH (DE) 1991-06-26 EP disclosed
US-4594421-A Substituted in position 2 with a phenyl compound RBS PHARMA (ROGER BELLON SCHOUM) S.P.A. (IT) 1986-06-10 US disclosed
EP-0151094-A2 Pharmacologically active imidazopyridine compounds RBS PHARMA (ROGER BELLON SCHOUM) S.p.A. (IT) 1985-08-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120004407-A1 METAL COMPLEXES HAVING AZABOROL LIGANDS AND ELECTRONIC DEVICE HAVING THE SAME ICOSLG, ERAL1, CTCF CYP1A2 1830/4885CYP2C19 2430/4885CXCR4 1277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.